

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **February 1, 2025** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the **February 1, 2025** updates for complete listings of products available by special authorization, restricted benefit/special authorization, products with changes to coverage, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change, discontinued listings and delisted products.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortages addressed for ADBL

Alberta Blue Cross has confirmed that the shortages for Rabeprazole 20 mg Enteric-Coated Tablet (DIN 02385457), manufactured by Sivem Pharmaceuticals ULC, Rabeprazole EC 20 mg Enteric-Coated Tablet (DIN 02356538), manufactured by Sanis Health Inc., and Sandoz Rabeprazole 20 mg Enteric-Coated Tablet (DIN 02314185) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **February 18, 2025**. The following grouping was removed from the Critical Supply Product List on **January 17, 2025**.

RABEPRAZOLE SODIUM

20 MG ENTERIC-COATED TABLET

00002415291	JAMP RABEPRAZOLE	JPC	\$ 0.1338
00002385457	RABEPRAZOLE	SIV	\$ 0.1338
00002356538	RABEPRAZOLE EC	SNS	\$ 0.1338
00002314185	SANDOZ RABEPRAZOLE	SDZ	\$ 0.1338
00002243797	PARIET	JAI	\$ 2.1788

continued next page

PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has confirmed that the shortages for Apo-Brivaracetam 100 mg Tablet (DIN 02538717) and Auro-Brivaracetam 100 mg Tablet (DIN 02539306) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **February 24, 2025**. The following grouping was removed from the Critical Supply Product List on **January 24, 2025**.

BRIVARACETAM

100 MG TABLET

00002538717	APO-BRIVARACETAM	APX	\$ 2.1600
00002539306	AURO-BRIVARACETAM	AUR	\$ 2.1600
00002452979	BRIVLERA	UCB	\$ 4.3200

Alberta Blue Cross has confirmed that the shortage for Teva-Bupropion XL 150 mg Extended-Release Tablet (DIN 02439654) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **March 3, 2025**. The following grouping was removed from the Critical Supply Product List on **January 30, 2025**.

BUPROPION HCL

150 MG EXTENDED-RELEASE TABLET

00002475804	TARO-BUPROPION XL	SPG	\$ 0.2926
00002439654	TEVA-BUPROPION XL	TEV	\$ 0.2926
00002275090	WELLBUTRIN XL	VCL	\$ 0.5883

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

